Gradient Investments’s Genetic Technologies Ltd. GENE Stock Holding History

Gradient Investments’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-438	Closed	-$1.82K	–	1924
2023 Q2	$1.82K	Buy	+438	New	+$2.17K	﹤0.01%	1185

Other funds holding GENE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Scarborough Advisors Annapolis, Maryland $871M AUM 21.96% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

PWA

Provenance Wealth Advisors Fort Lauderdale, Florida $945M AUM 17.16% 1-Year Est. Return

Gradient Investments's GENE Position: Q3 2023 in Review

Gradient Investments sold out of Genetic Technologies Ltd. (GENE) in Q3 2023, closing a stake of 438 shares — an estimated $1.82K sold.

Gradient Investments first reported a position in GENE in Q2 2023 and held it in 1 quarter. The position peaked at $1.82K in Q2 2023. 6 funds tracked by Wall St. Rank hold GENE as of Q3 2023.

Gradient Investments reported no remaining Genetic Technologies Ltd. position as of Q3 2023 after selling out during the quarter.
Gradient Investments sold 438 Genetic Technologies Ltd. shares in Q3 2023, an estimated $1.82K.
Gradient Investments first reported a position in Genetic Technologies Ltd. in Q2 2023 and held it in 1 quarter.
Gradient Investments's Genetic Technologies Ltd. position peaked at $1.82K in Q2 2023.
6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2023.

Based on Gradient Investments's 13F filing for Q3 2023, filed 27 Oct 2023.